SEC Form 4 · accession 0001562180-18-003068
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimi Iguchi
Officer — CFO & Treasurer
Period of report
Jun 19, 2018
Accepted (ET)
Jun 20, 2018 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 19, 2018 | M | 800 | $0.45 | A | 26,826 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $0.45 | Jun 19, 2018 | M | 800 | D | — | Sep 24, 2023 | Common Stock | 800 | 67,949 | D |
Explanation of responses
- F1This balance includes employee stock purchase plans shares.
- F2The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option vested in full on September 16, 2017, subject to continued service through such date.